Overview

Included because it may make injectable peptides obsolete for most people. It is a small molecule, not a peptide, so it survives digestion without the absorption enhancers and strict fasting rules that oral semaglutide requires.

Investigational — not approvedInvestigational at the time of review. Check current FDA status before relying on this page.

At a glance

Regulatory status	Not a peptide. Phase 3 (ATTAIN and ACHIEVE programs). Not approved at the time of review.
Drug class	Non-peptide small-molecule GLP-1 receptor agonist — orally bioavailable
Route	Oral, once daily
Half-life	~29–49 hours
Evidence rating	4/5 Strong Evidence rating 4 out of 5: Strong Consistent human randomized trials, or approval outside the United States.
Studied in	Phase 3 ATTAIN trials in obesity and ACHIEVE trials in type 2 diabetes; multiple phase 2 trials preceding them.

How it works

Binds the GLP-1 receptor at a site accessible to a small molecule, producing incretin signalling without a peptide backbone. Because it is not degraded by gut proteases, it needs no permeation enhancer and has no food or water restrictions.

Evidence base

Rated 4 of 5 — Strong. Consistent human randomized trials, or approval outside the United States.

Large phase 3 program with active and placebo comparators.
Regulatory status is the fastest-moving fact on this page.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Injection-free GLP-1 therapy Strong evidence

A daily tablet with no fasting window removes the single largest barrier to incretin therapy for most patients.
Weight loss in the GLP-1 range Strong evidence

Phase 3 obesity results showed mean weight reduction broadly comparable to injectable semaglutide.
Manufacturing scale Moderate evidence

Small-molecule synthesis avoids the peptide manufacturing bottleneck that has caused repeated GLP-1 shortages.
No food or water restrictions Strong evidence

Unlike oral semaglutide, which requires dosing fasted with a strict water volume and a 30-minute wait.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Not approved at the time of this review Serious

Regulatory decisions were pending; nothing here should be read as an approval.
GI adverse effects persist Moderate evidence

Nausea, vomiting and diarrhea occur at rates comparable to injectable GLP-1 agonists — the route changed, the receptor did not.
Daily dosing adherence Minor

A daily tablet is easier to start and easier to forget than a weekly injection.
Class contraindications still apply Serious

Thyroid C-cell and pancreatitis cautions are receptor-driven, not formulation-driven.
Not a peptide Minor

Listed here for context. Do not assume peptide-specific information applies to it.

Who should avoid it

Medullary thyroid carcinoma or MEN2 history
Pregnancy
Prior pancreatitis (relative)

If used under medical supervision, monitor

HbA1c, weight
GI tolerability during titration

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

Insulin and sulfonylureas — hypoglycemia risk
Fewer absorption interactions than oral semaglutide, since it needs no permeation enhancer

Regulatory & legal status

Investigational at the time of review. Check current FDA status before relying on this page.

Infographic

Orforglipron — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

weight lossoralnot a peptideGLP-1investigational

Related peptides in Metabolic & Weight

Terms used on this page

Permeation Enhancer: A permeation enhancer is an excipient that transiently increases how readily a mucosal barrier admits a co-formulated drug, making otherwise negligible absorption of peptides commercially useful.
Peptide Backbone: The peptide backbone is the repeating nitrogen, alpha-carbon and carbonyl-carbon chain shared by every peptide, and its limited rotational freedom determines which shapes the molecule can adopt.
The Incretin Effect: The incretin effect is the larger insulin response to oral glucose than to intravenous glucose matched for the same blood glucose profile, and it is mediated mainly by GLP-1 and GIP.
Glucagon-Like Peptide-1 (GLP-1): Glucagon-like peptide-1 is an incretin hormone released by intestinal L-cells after a meal that stimulates glucose-dependent insulin secretion and suppresses appetite.
Phase 3 Trial: A Phase 3 trial is the large confirmatory study, powered for a prespecified clinical endpoint, on which a marketing application and the resulting product label are built.
Placebo and Placebo Control: A placebo is an inactive intervention matched to the real one in appearance and route, used as a control arm so that improvement caused by the drug can be separated from improvement that would occur anyway.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.